Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.4SC, a German drug discovery and development company, and Sanwa Kagaku Kenkyusho, a Japanese pharmaceutical company, have achieved the first milestone and entered the next phase of a drug discovery collaboration which was started in January 2005.
Subscribe to our email newsletter
In order to achieve the milestone 4SC applied its proprietary virtual high throughput screening technology, 4Scan, to identify active agents against specific targets provided by Sanwa Kagaku Kenkyusho (SKK), followed by corresponding biological screening experiments.
In the next phase of the collaboration 4SC scientists will further optimize hits and leads with respect to certain properties like potency and selectivity.
The achievement of the first milestone triggers an undisclosed payment from SKK as well as the continuation of the partnership.
“We are extremely pleased with the quality and speed of the results achieved by 4SC,” commented Mr Satoshi Terao, SKK’s vice president for R&D. “In the last months we have built an excellent relationship and we are looking forward to a continued fruitful collaboration.”